OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cancer is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Linking pancreatic renewal and cancer initiation	1529
Computing brain metastasis impact	1086
Digging for treasures in the tumour interactome	920
INVADEseq to study the intratumoural microbiota at host single-cell resolution	563
An inhospitable site	528
Combining spatial transcriptomics and AI to enhance brain tumour diagnosis	494
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment	373
Oncofetal reprogramming in tumour development and progression	353
Fructose takes a detour to feed cancer	352
Emerging strategies to investigate the biology of early cancer	336
Artificial intelligence in cancer research, diagnosis and therapy	303
Combinatorial strategies to target RAS-driven cancers	298
Mapping the prostate cell family tree	292
How medical anthropology can contribute to cancer research	292
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma	291
Connie J. Eaves (1944–2024)	270
The recruitment of metastasis-associated monocytes	268
Antihistamines boost immunotherapy	263
Fighting cancer with fat	257
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’	251
Translating premalignant biology to accelerate non-small-cell lung cancer interception	239
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies	236
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel	229
Epithelial and stromal co-evolution and complicity in pancreatic cancer	228
Tertiary lymphoid structures as hubs of antitumour immunity	214

Context-dependent functions of pattern recognition receptors in cancer	209
Targeting transcription cycles in cancer	208
No mutation, tumour initiation	208
Impersonating neurons	191
Nanoreceptors take down mutant p53	186
Under pressure	186
Gut microbes produce novel genotoxic metabolites	179
Tumour EVPs disrupt liver function	177
Dendritic cells rise and shine	176
Removing barriers to address sex differences in anticancer drug toxicity	175
Persistence is key	174
Thelpers? More like Ttroublemakers	167
AACR 2025	166
Measuring HLA disruption using MHC Hammer	161
Defining a ‘cells to society’ research framework for appendiceal tumours	159
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer	155
Remodelling of the tumour microenvironment by the kallikrein-related peptidases	154
3D bioprinted cancer models: from basic biology to drug development	152
How chemokines organize the tumour microenvironment	149
Tumour–host interactions through the lens of Drosophila	148
Natural killer cells in antitumour adoptive cell immunotherapy	146
Points of entry for tumour-infiltrating lymphocytes	142
B-ring sterols to the rescue	141
Bone voyage: immune crosstalk sets sail	139
Identifying spatial cellular structures with SPACE-GM	127
In-depth organoid profiling of pancreatic cancer	122
Visualizing intratumoural heterogeneity with EpicMIBI	120
Metabolic interplays between the tumour and the host shape the tumour macroenvironment	116
Regulatory T cells in the tumour microenvironment	114
Environmental endocrine disruptors: rethinking the origins of early-onset ER+ breast cancer	109
The path to leptomeningeal metastasis	107
Un-Fair Skin: racial disparities in acral melanoma research	105
Leveraging the replication stress response to optimize cancer therapy	101
Linking cell mechanical memory and cancer metastasis	100
The plasticity of mRNA translation during cancer progression and therapy resistance	100
Dynamics and specificities of T cells in cancer immunotherapy	97
Understanding and addressing race disparities in childhood cancer outcomes	95
In situ decellularization of tissues to resolve the tumour-associated matrix	95
Encoding spatial tumour dynamics with Starfysh	94
Deciphering the cancer genome and epigenome	91
Race influences the tumour microbiome	91
The link between vitamin D and prostate cancer	91
Taming TAMs in brain metastases	91
Polygenic scores in cancer	90
Targeted protein degradation for cancer therapy	89
Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic	88
RNA splicing dysregulation and the hallmarks of cancer	87
Cancer nanomedicine	87
Acetyl-CoA metabolism in cancer	86
Z-nucleic acids give immunotherapy a boost	84

Local CAR manufacturing	83
Author Correction: Antibody-based proteomics: fast-tracking molecular diagnostics in oncology	81
Parity modulates epithelial–immune cell communication	78
Right ON target: a new RAS-GTP inhibitor	77
Prime editing GEMMs to model cancer mutations	76
A trojan horse to target spliceosome mutant cells	76
NOTUM-mediated stem cell competition in CRC	73
Expanding the utility of precision oncology knowledge bases	72
Integrative medicine in oncology: redefining the standard of care	69
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities	66
Chromothripsis in cancer	65
Defining precancer: a grand challenge for the cancer community	63
Tertiary lymphoid structures in anticancer immunity	63
Targeting ferroptosis as a vulnerability in cancer	62
Starting a new job	61
Quantum probes in cancer research	59
Functional lineage tracing to study the clonal evolution of therapy resistance	58
Neutrophils: a roadblock for immunotherapy	57
In vivo labelling system to study cell neighbourhoods	53
Revealing genomic secrets of archival FFPE samples	52
Judith Campisi (1948–2024)	51
New pathogen on the block	47
Inferring cancer metabolism from gene-expression data	46
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart	45
Glycogen condensates drive tumorigenesis by trapping Hippo kinases	45
The present and future of the Cancer Dependency Map	44
Recent advances in therapeutic cancer vaccines	44
Carcinogenesis at single-cell resolution	41
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data	41
Bidirectional CART.BiTE cells bring new hope	40
Cell states can give tumorigenesis a head start	40
Patient-derived organoids unveil sarcoma vulnerabilities	38
Global post-mortem tissue donation programmes to accelerate cancer research	36
Evolution and progression of Barrett’s oesophagus to oesophageal cancer	34
Epigenomic heterogeneity as a source of tumour evolution	34
Transfer RNAs as dynamic and critical regulators of cancer progression	32
A timeline of tumour-associated macrophage biology	31
Author Correction: Integrative medicine in oncology: redefining the standard of care	31
Developing dietary interventions as therapy for cancer	31
Traject3d for studying 3D cellular heterogeneity	31
We cannot ignore the cancer risks of wildfires	30
Fcγ receptors and immunomodulatory antibodies in cancer	28
Harnessing the influenza virus to fight cancer	28